Skride Andris, Sablinskis Matiss, Sablinskis Kristaps, Lejniece Sandra, Lejnieks Aivars, Klepetko Walter, Lang Irene M
Riga Stradins University, Riga, Latvia.
Department of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
Am J Case Rep. 2018 Oct 19;19:1245-1248. doi: 10.12659/AJCR.909778.
BACKGROUND Antiphospholipid syndrome is an autoimmune disorder characterized by a hypercoagulable state associated with circulating antiphospholipid antibodies. The presence of antiphospholipid antibodies can result in a variety of clinical symptoms, such as thrombocytopenia, stillbirth, endocardial pathologies, and recurrent pulmonary embolism. CASE REPORT We present the case of a 23-year-old man with antiphospholipid syndrome and chronic thromboembolic pulmonary hypertension who developed severe thrombocytopenia. The patient died from right heart failure before the thrombocytopenia could be managed, preventing performance of a pulmonary endarterectomy procedure. CONCLUSIONS Managing platelet counts in patients with antiphospholipid syndrome prior to major surgery is very problematic, and requires similar treatment strategy as in patients with immune thrombocytic thrombocytopenia. Platelet transfusions may further decrease platelet count, as it can trigger formation of new antibodies.
抗磷脂综合征是一种自身免疫性疾病,其特征为与循环抗磷脂抗体相关的高凝状态。抗磷脂抗体的存在可导致多种临床症状,如血小板减少、死产、心内膜病变和复发性肺栓塞。病例报告:我们报告一例23岁患有抗磷脂综合征和慢性血栓栓塞性肺动脉高压的男性患者,该患者出现了严重的血小板减少。在血小板减少得到处理之前,患者死于右心衰竭,从而无法进行肺动脉内膜剥脱术。结论:在进行大手术前,管理抗磷脂综合征患者的血小板计数非常棘手,需要采用与免疫性血小板减少症患者相似的治疗策略。血小板输注可能会进一步降低血小板计数,因为它可触发新抗体的形成。